A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...
Partnership to Bolster Solid Biosciences’ Gene Therapy Pipeline, Including AAV Process Development, Scale Up and cGMP Manufacturing Services Forge will provide an adeno-associated viral (AAV) vector ...
Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Plasmid DNA and Viral Vector Manufacturing Services With over 20 years of plasmid DNA and viral vector ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today ...
North America dominated the viral vector & plasmid DNA manufacturing market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...
Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...
BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results